May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Risk for Choroidal Neovascularization in the Fellow Eye of Patients on Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration
Author Affiliations & Notes
  • I. A. Barbazetto
    Ophthalmology, Vitreous Retina Macula Consultant NY, New York, New York
  • K. Kumar
    Medicine, NYU, New York, New York
  • H. Karamchandani
    Ophthalmology, Vitreous Retina Macula Consultant NY, New York, New York
  • D. Rabinowitz
    Department of Statistics, Columbia University, New York, New York
  • B. Takahashi
    Ophthalmology, Vitreous Retina Macula Consultant NY, New York, New York
  • L. A. Yannuzzi
    Ophthalmology, Vitreous Retina Macula Consultant NY, New York, New York
  • K. Freund
    Ophthalmology, Vitreous Retina Macula Consultant NY, New York, New York
  • Footnotes
    Commercial Relationships  I.A. Barbazetto, None; K. Kumar, None; H. Karamchandani, None; D. Rabinowitz, None; B. Takahashi, None; L.A. Yannuzzi, None; K. Freund, None.
  • Footnotes
    Support  The Macula Foundation, Inc.,
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 256. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      I. A. Barbazetto, K. Kumar, H. Karamchandani, D. Rabinowitz, B. Takahashi, L. A. Yannuzzi, K. Freund; Risk for Choroidal Neovascularization in the Fellow Eye of Patients on Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2008;49(13):256. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The presence of choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) is a known risk factor for the development of CNV in the fellow eye. Recent studies suggest that a small amount of systemic uptake after intraocular injection of anti-VEGF medication may have a therapeutic effect on the fellow eye. 1 The aim, of this study was to assess the risk of developing CNV in the fellow eye of patients treated with intravitreal anti-VEGF for neovascular AMD.

Methods: : 1092 charts of patients treated with intravitreal ranibizumab or bevacizumab (Genentech Inc., CA) for neovascular AMD were reviewed. Patients with unilateral neovascular disease were selected. Visual acuity as well as lesion characteristics on fluorescein angiography, color fundus photography and optical coherence tomography (OCT) were evaluated at baseline and follow-up examinations. Cumulative risk analysis was performed using Kaplan-Meier survival statistics; associated risk factors were analyzed using a chi-square test.

Results: : 222 patients (82 male, 140 female; mean age = 80 years) were included in this study. The mean follow-up time was 11.43 months (range = 1 - 29). Patients received an average of 5.82 injections (range = 1-17) of anti-VEGF medication. The cumulative risk of developing CNV in the fellow eye was 4.8% at 12 months and 11.5% at 24 months. Patients were more likely to develop CNV if the fellow eye had additional risk factors such as soft indistinct drusen and/or pigment hyperplasia. The neovascular subtype and lesion composition in the treated eye did not reach statistical significance as independent risk factors.

Keywords: age-related macular degeneration • choroid: neovascularization • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×